These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. Roman YM; Hernandez AV; White CM Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120 [TBL] [Abstract][Full Text] [Related]
7. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Nidorf SM; Thompson PL Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286 [TBL] [Abstract][Full Text] [Related]
8. The Emerging Role of Inflammation in Cardiovascular Disease. Martinez BK; White CM Ann Pharmacother; 2018 Aug; 52(8):801-809. PubMed ID: 29557210 [TBL] [Abstract][Full Text] [Related]
9. [Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?]. Hoogeveen RM; Stroes ESG; Cornel JH Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201620 [TBL] [Abstract][Full Text] [Related]
11. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis. Hafiane A; Daskalopoulou SS Pharmacol Res; 2022 Apr; 178():106157. PubMed ID: 35257900 [TBL] [Abstract][Full Text] [Related]
12. Update on the Inflammatory Hypothesis of Coronary Artery Disease. Boland J; Long C Curr Cardiol Rep; 2021 Jan; 23(2):6. PubMed ID: 33409720 [TBL] [Abstract][Full Text] [Related]
13. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents? Ridker PM Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469 [No Abstract] [Full Text] [Related]
14. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Golia E; Limongelli G; Natale F; Fimiani F; Maddaloni V; Pariggiano I; Bianchi R; Crisci M; D'Acierno L; Giordano R; Di Palma G; Conte M; Golino P; Russo MG; Calabrò R; Calabrò P Curr Atheroscler Rep; 2014 Sep; 16(9):435. PubMed ID: 25037581 [TBL] [Abstract][Full Text] [Related]
15. Statins and other agents for vascular inflammation. Owens CD J Vasc Surg; 2012 Dec; 56(6):1799-806. PubMed ID: 23017371 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131 [TBL] [Abstract][Full Text] [Related]
17. The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials. Passacquale G; Di Giosia P; Ferro A Cardiovasc Res; 2016 Jan; 109(1):9-23. PubMed ID: 26410367 [TBL] [Abstract][Full Text] [Related]
18. Inflammatory and Cholesterol Risk in the FOURIER Trial. Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884 [TBL] [Abstract][Full Text] [Related]
19. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis. Kottoor SJ; Arora RR J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850 [TBL] [Abstract][Full Text] [Related]
20. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Martínez GJ; Celermajer DS; Patel S Atherosclerosis; 2018 Feb; 269():262-271. PubMed ID: 29352570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]